Methods for diagnosing prostatic adenocarcinoma

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

435 723, 435 79, 435 792, 436 63, 436 64, 436518, G01N 3353, G01N 33574, G01N 33542, G01N 33537

Patent

active

057100071

ABSTRACT:
The present invention relates to a method for diagnosing prostatic adenocarcinoma (CAP) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is less than about 7%, then the patient is diagnosed as having CAP. The present method can also be used on patients that have a total PSA of at least 10.1 ng/ml, but have also had a negative prostate biopsy.

REFERENCES:
patent: 5501983 (1996-03-01), Lilja et al.
Luderer, A. A. et al, "Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of the total prostate-specific antigen" Urology, vol. 42 (2), pp. 187-191, Aug. 1995.
Prestigiacomo A. F. et al, "Clinical usefulness of free and complexed PSA" Scan. J. Clin. Lab. Invest. vol. 55 (Supple. 221), pp. 32-34, Apr. 28, 1995.
Christensson, A. et al, "Serum prostate specific antigen complexed to alpha 1 anti-chymotrypsin as an indicator of prostate cancer" J. Urol. vol. 150 (1) pp. 100-105, Jul. 1993.
Stenman, U.-H. et al, "Serum concentrations of prostate specific antigen and its complex with a1-anti-chymotryspin before diagnosis of prostate cancer" The Lancet, vol. 344, pp. 1594-1598, Dec. 1994.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods for diagnosing prostatic adenocarcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for diagnosing prostatic adenocarcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing prostatic adenocarcinoma will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-724467

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.